Cost-effectiveness of cryptococcal antigen screening at CD4 counts of 101–200 cells/µL in Botswana
Year: 2021
Type: article
Abstract: Background: Cryptococcal antigen (CrAg) screening in individuals with advanced HIV reduces cryptococcal meningitis (CM) cases and deaths. The World Health Organization recently recommended increasing screening thresholds from CD4 ≤100 cells/µL to ≤200 cells/µL. CrAg screening at CD4 ≤100 cells/µL is cost-effective; however, the cost-effectiveness of screening patients with CD4 101–200 cells/µL requires evaluation. Methods: Using a decision analytic model with Botswana-specific cost and clinical estimates, we evaluated CrAg screening and treatment among individuals with CD4 counts of 101–200 cells/µL. We estimated the number of CM cases and deaths nationally and treatment costs without screening. For screening we modeled the number of CrAg tests performed, number of CrAg-positive patients identified, proportion started on pre-emptive fluconazole, CM cases and deaths. Screening and treatment costs were estimated and cost per death averted or disability-adjusted life year (DALY) saved compared with no screening. Results: Without screening, we estimated 142 CM cases and 85 deaths annually among individuals with CD4 101–200 cells/µL, with treatment costs of $368,982. With CrAg screening, an estimated 33,036 CrAg tests are performed, and 48 deaths avoided (1,017 DALYs saved). While CrAg screening costs an additional $155,601, overall treatment costs fall by $39,600 (preemptive and hospital-based CM treatment), yielding a net increase of $116,001. Compared to no screening, high coverage of CrAg screening and pre-emptive treatment for CrAg-positive individuals in this population avoids one death for $2440 and $114 per DALY saved. In sensitivity analyses assuming a higher proportion of antiretroviral therapy (ART)-naïve patients (75% versus 15%), cost per death averted was $1472; $69 per DALY saved. Conclusions: CrAg screening for individuals with CD4 101–200 cells/µL was estimated to have a modest impact, involve additional costs, and be less cost-effective than screening populations with CD4 counts ≤100 cells/µL. Additional CrAg screening costs must be considered against other health system priorities.
Source: Wellcome Open Research
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,128
Funders: Pfizer, University of Pennsylvania, Wellcome Trust, Centers for Disease Control and Prevention Foundation, National Institute for Health and Care Research, Department of Health and Social Care, National Institutes of Health, Centers for Disease Control and Prevention, Center for AIDS Research, University of Washington, Medical Research Council, National Institute of Allergy and Infectious Diseases
Awards: G27772751, G2874871036, Cryptococcal antigen screening for the prevention of cryptococcal meningitis in the HIV "treat-and-treat" era: A prospective cohort and semi-quantitative lateral flow assay validation study, A detailed costing of Cryptococcal Meningitis prevention and treatment in Botswana, Penn Center for AIDS Research, Host Defense Training in Allergy and Infectious Diseases
OpenAlex ID: W3134476967
